...
首页> 外文期刊>Journal of Cancer >Diagnostic, clinicopathologic, therapeutic and prognostic value of Plasma Heat Shock Protein 90 levels in patients with advanced Gastrointestinal Carcinoma
【24h】

Diagnostic, clinicopathologic, therapeutic and prognostic value of Plasma Heat Shock Protein 90 levels in patients with advanced Gastrointestinal Carcinoma

机译:晚期胃肠癌患者血浆热休克蛋白90水平的诊断,临床病理学,治疗和预后价值

获取原文

摘要

Purpose: Heat shock protein 90 (HSP90) is a critical molecular chaperone for protein folding, intracellular disposition and regulation of tumor biological behavior in the extracellular space. HSP90 has received much attention due to its specific effect in gastrointestinal cancer. This clinical study sought to determine whether HSP90 in plasma may serve as a biomarker in patients with advanced gastrointestinal carcinoma. Methods: Using human plasma samples of advanced gastrointestinal carcinoma, we investigated the specific value of HSP90 in gastrointestinal cancer from a clinical perspective. Results: In summary, plasma levels of HSP90 were shown to be higher in patients with gastric cancer (GC) or colorectal cancer (CRC) than in controls with benign gastrointestinal diseases. In both GC and CRC patients, HSP90 was significantly associated with live metastasis. Higher HSP90 levels were more frequent in CRC patients with hazardous or harmful alcohol consumption habits. Patients with RAS mutations had higher HSP90 levels in CRC. Compared with Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 19-9 (CA19-9), HSP90 benefited patients by enhancing diagnostic sensitivity and the Youden index. The levels of HSP90 were inversely associated with short-term efficacy in GC patients who had received fluorouracil/platinum-based advanced first-line treatment. When first-line therapy failed, plasma HSP90 levels in patients with GC were significantly increased. In terms of progression-free survival (PFS), patients with GC or CRC who had low levels of HSP90 were not significantly different from those with high levels of HSP90. Univariate and multivariate analyses demonstrated that HSP90 was not an independent prognostic predictor for GC and CRC patients with PFS. However, RAS mutation was an independent prognostic factor for poor PFS in CRC patients. Conclusions: Plasma HSP90 levels have potential diagnostic value in advanced gastrointestinal carcinoma and therapeutic predictive value in GC.? The author(s).
机译:目的:热休克蛋白90(HSP90)是用于蛋白质折叠,细胞外空间肿瘤生物学行为的临界分子伴侣伴蛋白质折叠,细胞内处理和调节。由于其在胃肠癌的特定效果,HSP90受到了很多关注。该临床研究寻求确定血浆中HSP90是否可以用作晚期胃肠癌患者的生物标志物。方法:采用人类血浆样品进行晚期胃肠癌,我们从临床角度调查了HSP90在胃肠癌中的特异性值。结果:总之,胃癌(GC)或结肠直肠癌(CRC)患者的血浆水平高于良性胃肠疾病的对照。在GC和CRC患者中,HSP90与活转移有显着相关。在CRC患者患有危险性或有害的酒精消费习惯的CRC患者中更高的HSP90水平。 RAS突变患者在CRC中具有较高的HSP90水平。与癌胚抗原(CEA)和碳水化合物抗原(CA19-9)相比,HSP90通过提高诊断敏感性和YOYDEN指数而受益。 HSP90的水平与GC患者的短期疗效与接受氟尿嘧啶/铂类先进的先进的一线治疗的短期疗效相反。当一线疗法失败时,GC患者的血浆HSP90水平显着增加。在无进展的生存期(PFS)方面,患有低水平Hsp90水平的GC或CRC的患者与具有高水平HSP90的患者没有显着差异。单变量和多变量分析证明了HSP90不是GC和CRC患者的独立预测预测因子。然而,RAS突变是CRC患者PFS差的独立预后因素。结论:血浆HSP90水平具有晚期胃肠癌癌的潜在诊断价值和GC的治疗性预测值。作者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号